Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
16 pending office actions • 6 art units • 12 examiners • 0 of 16 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Merus N V maintains a portfolio in the Biotechnology & Pharmaceuticals technology area with 16 pending office actions. These actions are distributed across 12 distinct examiners and 6 distinct art units. The busiest examiner for the company is WEHBE, ANNE MARIE SABRINA, who is currently handling 2 pending office actions.
The distribution of 16 pending office actions among 12 distinct examiners suggests that the portfolio is not overly concentrated under any single individual. The 6 distinct art units involved show that the company's intellectual property spans multiple sub-specialties within the Biotechnology & Pharmaceuticals sector. This diversity requires managing various examiner styles and art unit tendencies simultaneously.
WEHBE, ANNE MARIE SABRINA, as the busiest examiner with 2 pending office actions, represents a small portion of the total workload. This indicates that the portfolio's success is dependent on a wide range of examiner interactions rather than a single point of contact. The ratio of 12 distinct examiners to these pending actions reflects a high degree of variety in the prosecution landscape.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (6%) |
| §103 only | 2 (12%) |
| §102 only | 1 (6%) |
| §112 only | 3 (19%) |
| Double-patenting + other | 3 (19%) |
| Multi-statute (no §101) | 5 (31%) |
| No statute on record | 1 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEHBE, ANNE MARIE SABRINA | 2 | 57.2% | +43.4% |
| NICKOL, GARY B | 2 | 47.1% | +31.1% |
| BRISTOL, LYNN ANNE | 2 | 63.4% | +39.8% |
| ALSOMAIRY, SARAH ABDOALATIF | 2 | 57.8% | +30.2% |
| CHASE, CAROL ANN | 1 | 42.6% | +84.7% |
| HOPPE, EMMA RUTH | 1 | 42.1% | +56.8% |
| LI, RUIXIANG | 1 | 59.5% | +18.6% |
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
| SHUPE, ELIZABETH A | 1 | 66.2% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17431044 | COMBINATIONS OF BINDING MOIETIES THAT BIND EGFR, HER2 AND HER3 | ALSOMAIRY, SARAH ABDOALATIF | 30d overdue |
| 18566982 | NEW NRG1 FUSIONS, FUSION JUNCTIONS AND METHODS FOR DETECTING THEM | HOPPE, EMMA RUTH | — |
| 18460482 | ANTIBODY PRODUCING NON-HUMAN ANIMALS | WEHBE, ANNE MARIE SABRINA | — |
| 18449460 | ERBB-2 AND ERBB3 BINDING BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CELLS THAT HAVE AN NRG1 FUSION GENE | LI, RUIXIANG | — |
| 18257804 | MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER | NICKOL, GARY B | — |
| 17431041 | PRODUCING COMPOSITIONS COMPRISING TWO OR MORE ANTIBODIES | FAUST, AMBER KATHLEEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17431044 | COMBINATIONS OF BINDING MOIETIES THAT BIND EGFR, HER2 AND HER3 | ALSOMAIRY, SARAH ABDOALATIF | 30d overdue |
| 18257528 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | NICKOL, GARY B | 23d overdue |
| 18251832 | MEANS AND METHODS FOR TREATING SUBJECTS WITH ERBB3 MUTATION POSITIVE CANCER | GODDARD, LAURA B | 6d |
| 18062871 | BINDING MOLECULES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL | MOSELEY II, NELSON B | 22d |
| 17926283 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | BRISTOL, LYNN ANNE | 27d |
| 17921042 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | SHUPE, ELIZABETH A | 29d |
| 18419527 | ANTIBODY THAT BINDS ERBB-2 AND ERBB-3 | CHASE, CAROL ANN | 42d |
| 17755196 | MEANS AND METHODS FOR TREATING SUBJECTS WITH HER2 AND HER3 POSITIVE CANCER | BRISTOL, LYNN ANNE | 70d |
| Art Unit | Apps |
|---|---|
| 1643 | 6 |
| 1646 | 3 |
| 1634 | 2 |
| 1674 | 2 |
| 1642 | 2 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18419527 | ANTIBODY THAT BINDS ERBB-2 AND ERBB-3 | CHASE, CAROL ANN | 1646 | Other | Final Rejection | 42d | Pending | Jan 22, 2024 |
| 18566982 | NEW NRG1 FUSIONS, FUSION JUNCTIONS AND METHODS FOR DETECTING THEM | HOPPE, EMMA RUTH | 1683 | §101§102§112DP | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18464173 | ANTIBODY PRODUCING NON-HUMAN ANIMALS | WEHBE, ANNE MARIE SABRINA | 1634 | §102 | Final Rejection | — | Pending | Sep 08, 2023 |
| 18460482 | ANTIBODY PRODUCING NON-HUMAN ANIMALS | WEHBE, ANNE MARIE SABRINA | 1634 | §102§103§112Other | Final Rejection | — | Pending | Sep 01, 2023 |
| 18449460 | ERBB-2 AND ERBB3 BINDING BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CELLS THAT HAVE AN NRG1 FUSION GENE | LI, RUIXIANG | 1674 | §103§112 | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18257804 | MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER | NICKOL, GARY B | 1643 | §102§103§112 | Final Rejection | — | Pending | Jun 15, 2023 |
| 18257528 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | NICKOL, GARY B | 1643 | §103 | Final Rejection | 23d overdue | Pending | Jun 14, 2023 |
| 18251832 | MEANS AND METHODS FOR TREATING SUBJECTS WITH ERBB3 MUTATION POSITIVE CANCER | GODDARD, LAURA B | 1642 | §102§103§112DP | Final Rejection | 6d | Pending | May 04, 2023 |
| 18062871 | BINDING MOLECULES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL | MOSELEY II, NELSON B | 1642 | §112 | Final Rejection | 22d | Pending | Dec 07, 2022 |
| 17926283 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | 27d | Pending | Nov 18, 2022 |
| 17921042 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | SHUPE, ELIZABETH A | 1643 | §103DP | Non-Final OA | 29d | Pending | Oct 24, 2022 |
| 17759728 | MEANS AND METHOD FOR MODULATING IMMUNE CELL ENGAGING EFFECTS | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Final Rejection | — | Pending | Jul 29, 2022 |
| 17755196 | MEANS AND METHODS FOR TREATING SUBJECTS WITH HER2 AND HER3 POSITIVE CANCER | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | 70d | Pending | Apr 22, 2022 |
| 17632181 | TREATMENT OF CANCER WITH A COMBINATION OF AN ANTIBODY THAT BINDS LGR5 AND EGFR AND A TOPOISOMERASE I INHIBITOR | MIDDLETON, DANAYA L | 1674 | §103§112DP | Non-Final OA | 28d | Pending | Feb 01, 2022 |
| 17431041 | PRODUCING COMPOSITIONS COMPRISING TWO OR MORE ANTIBODIES | FAUST, AMBER KATHLEEN | 1643 | §102§103§112 | Non-Final OA | — | Pending | Aug 13, 2021 |
| 17431044 | COMBINATIONS OF BINDING MOIETIES THAT BIND EGFR, HER2 AND HER3 | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103§112 | Final Rejection | 30d overdue | Pending | Aug 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial